Results 181 to 190 of about 16,645 (269)

Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective

, 2017
Katherine A. Vilain, Ming‐Chin Yang, Elise Chia‐Hui Tan, Kaijun Wang, Haiyan Li, Wan Hsuan Hsu, Robert P. Giugliano, David J. Cohen, Elizabeth A. Magnuson   +8 more
openalex   +1 more source

Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation

, 2021
Jan Steffel, Christian T. Ruff, Ophelia Yin, Eugene Braunwald, Jeong‐Gun Park, Sabina A. Murphy, Stuart J. Connolly, Elliott M. Antman, Robert P. Giugliano   +8 more
openalex   +1 more source

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of CardiologyWorking Group on Cardiovascular Pharmacotherapy and European Society of CardiologyWorking Group on Thrombosis [PDF]

, 2015
Agewall, Stefan, Atar, Dan, Drexel, Heinz, Elkjær Husted, Steen, Kaski, Juan, Kjeldsen, Keld, Koller, Lorenz, Lewis, Basil, Lip, Gregory, Morais, João, Niessner, Alexander, Storey, Robert, Tamargo, Juan, Torp-Pedersen, Christian, Verheugt, Freek, Wassmann, Sven   +15 more
core   +1 more source

Non-invasive dentistry method for clinical determination of bleeding time: evaluation in subjects with and without direct oral anticoagulant therapy. [PDF]

Thromb J
Pfützner A, Zimmermann A, Wendling S, Jantz J, Shing RNK, Pilot J, Gillen D, Invest JCF, Thomé N, Ernst CP, Willershausen B.   +10 more
europepmc   +1 more source

Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients

, 2021
Valerio Langella, Roberta Bottino, Antonio Asti, Giulio Maresca, Gisella Di Palma, D Pomponi, Claudia Sassone, Egidio Imbalzano, Vincenzo Russo   +8 more
openalex   +2 more sources

Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study). [PDF]

Front Pharmacol
Montero-Balosa MC, Limón-Mora JA, Leal-Atienza A, García-Robredo B, Sánchez-Villegas P, Isabel-Gómez R, Aguado-Romeo MJ, Luque Romero LG, Molina-López MT.   +8 more
europepmc   +1 more source

The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist

, 2018
Kazuhiro Shimizu, Takuo Iiduka, Shuji Sato, Hajime Kiyokawa, Takahiro Nakagami, Hiroshi Mikamo, Masayo Kawazoe, M Takahashi, Mahito Noro   +8 more
openalex   +2 more sources

No clinically relevant interaction of voriconazole with microdosed apixaban, edoxaban and rivaroxaban

, 2018
Gerd Mikus, Marlene Schaumaeker, Kathrin I. Foerster, Marie‐Louise Lehmann, Walter E. Haefeli   +4 more
openalex   +2 more sources

Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System. [PDF]

Pharmaceuticals (Basel)
Cheon S, Park J, Oh D, Kim YS, Chung JE.
europepmc   +1 more source

Discrepancies in Recommendations on Pharmacokinetic Drug Interactions for Anticancer Medications and Direct Oral Anticoagulants (DOAC): A Comparative Analysis of Different Clinical Decision Support Systems and Sources. [PDF]

Pharmaceuticals (Basel)
Nowinski K, Chaireti R.
europepmc   +1 more source